Target
Mitogen-activated protein kinase 9
Ligand
BDBM50334000
Substrate
n/a
Meas. Tech.
ChEMBL_701206 (CHEMBL1648826)
IC50
61±n/a nM
Citation
 Probst, GDBowers, SSealy, JMTruong, APHom, RKGalemmo, RAKonradi, AWSham, HLQuincy, DAPan, HYao, NLin, MTóth, GArtis, DRZmolek, WWong, KQin, ALorentzen, CNakamura, DFQuinn, KPSauer, JMPowell, KRuslim, LWright, SChereau, DRen, ZAnderson, JPBard, FYednock, TAGriswold-Prenner, I Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett 21:315-9 (2010) [PubMed]  Article 
Target
Name:
Mitogen-activated protein kinase 9
Synonyms:
JNK-55 | JNK2 | JNK2/JNK3 | MAPK9 | MK09_HUMAN | Mitogen-Activated Protein Kinase 9 (JNK2) | Mitogen-activated protein kinase 8/9 | PRKM9 | SAPK1A | Stress-activated protein kinase JNK2 | c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 2 (JNK2)
Type:
Enzyme
Mol. Mass.:
48131.49
Organism:
Homo sapiens (Human)
Description:
JNK-2 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology).
Residue:
424
Sequence:
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR
  
Inhibitor
Name:
BDBM50334000
Synonyms:
3-(2-(cyclohexylamino)pyridin-4-yl)-4-(naphthalen-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-1,2,4-triazol-5(4H)-one | CHEMBL1644638
Type:
Small organic molecule
Emp. Form.:
C29H33N5O2
Mol. Mass.:
483.6046
SMILES:
O=c1n(CC2CCOCC2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1
Structure:
Search PDB for entries with ligand similarity: